期刊文献+

胶质瘤环氧化酶-2抑制剂塞来昔布对肿瘤微环境及生物学行为的影响 被引量:6

Effect of inhibiting cyclooxygenase-2 expression on glioma immune microenvironment and biological behavior
原文传递
导出
摘要 目的 探讨选择性环氧化酶-2(cyclooxygenase-2,COX-2)抑制剂塞来昔布(celecoxib)对大鼠脑胶质瘤免疫微环境及生物学行为的影响.方法 建立大鼠脑胶质瘤模型,观察celecoxib治疗后肿瘤大小及大鼠生存期;免疫组化法检测肿瘤组织COX-2、转化生长因子-β(transforming growth factor-beta,TGF-β)、血管内皮生长因子(vascular endothelial growth factor,VEGF)蛋白表达;流式细胞术检测肿瘤微环境CD4+CD25+T细胞亚群数量;酶联免疫法(ELISA)检测大鼠血清中前列环素E2(Prostaglandin E2,PGE2)、白介素-l0(IL-l0)、白介素-12(IL-12)分泌水平.结果 Celecoxib治疗组肿瘤体积明显小于对照组[(103.67±5.54) mm3,(151.60±8.34) mm3,P<0.01],并可延长大鼠生存期[(42.87± 1.72)d,(26.13± 1.53)d,P<0.01],肿瘤组织中COX-2、VEGF及TGF-β蛋白的表达均出现下调,其肿瘤微环境中CD4+CD25+T细胞亚群比例明显降低(5.32%,7.84%,P<0.05).血清中PGE2与IL-10水平明显下降[(223.66±33.79)pg/ml,(344.15±41.09) pg/ml,(98.69± 10.99) pg/ml,(133.37± 13.15) pg/ml,P<0.01],而IL-12分泌明显增多[(237.20±37.31) pg/ml,(117.90±19.20) pg/ml,P<0.01].结论 Celecoxib可通过多种途径改善肿瘤局部免疫微环境,从而改变肿瘤的生物学行为,延缓肿瘤发展,并为肿瘤治疗提供良好的基础环境. Objective To investigate the effect of celecoxib,a selective inhibitor of cyclooxygenase-2 (COX-2),on glioma immune microenvironment and biological action in rat.Methods After treated with celecoxib,tumor volume and survive time were observed in a rat glioma model.COX-2,transforming growth factor-beta (TGF-β) and vascular endothelial growth factor(VEGF) expression in tumor tissue were detected using immunehistory and CD4 + CD25 + T cells was detected by flowcytometry.By using enzyme-linked immunosorbent assay (ELISA),the production of prostaglandin(PGE2),interlukin 10(IL-10) and interlukin 12(IL-12) were detected in rat serum.Results Tumor volume decreased after treated with celecoxib ((103.67±5.54) mm3,(151.60±8.34)mm3,P<0.01) and survive time of animals were prolonged ((42.87±1.72) d,(26.13±1.53)d,P<0.01).Expression of COX-2,TGF-β and VEGF in tumor tissue was down regulated after treated with celecoxib and number of CD4+CD25 + T cells were decreased (5.32%,7.84%,P< 0.05).PGE2,IL-10 production in serum was obviously decreased by treatment of celecoxib ((223.66±33.79) pg/ml,(344.15±41.09) pg/ml,(98.69± 10.99) pg/ml,(133.37± 13.15) pg/ml,P<0.01) while the production of IL-12 was increased ((237.20±37.31) pg/ml,(117.90±19.20) pg/ml,P<0.01).Conclusion Celecoxib may improve the status of immunosuppression of rat glioma by several pass ways and modify tumor biological action.Celecoxib may give a good microenvironment for immunotherapy of gliomas.
出处 《中华行为医学与脑科学杂志》 CAS CSCD 北大核心 2014年第2期107-109,共3页 Chinese Journal of Behavioral Medicine and Brain Science
基金 山东省自然科学基金项目(ZR2009CQ015)
关键词 胶质瘤 环氧化酶-2 肿瘤微环境 免疫逃逸 Gliomas Cyclooxygenase 2 Tumor microenvironment Immune escape
  • 相关文献

参考文献13

  • 1Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment[J] . Genes Dev, 2007, 21 (10) :2683-2710.
  • 2Pellegatta S, Cuppini L, Finocchiaro G. Brain cancer immunoediting , novel examples provided by immunotherapy of malignant gliomas[J] . Expert Rev Anticancer Ther ,2011,11 (11) : 1759-1774.
  • 3EI-Sayed M, Taba MM. Immunohistochemical expression of cycloxyge?nase-2 in astrocytoma: correlation with angiogenesis, tumor progression and survival[J] .Turk Neurosurg,2011 ,21 (1) : 27-35.
  • 4张洪涛,田苗,修春明,刘杰,崔广强,王云波,潘树茂.环氧化酶-2和表皮生长因子受体在星形细胞瘤中表达的意义[J].中国医师杂志,2010,12(2):185-187. 被引量:6
  • 5张向萍,张洪涛,修春明,等.抑制COX-2/PGE2通路对胶质瘤细胞免疫抑制因子表达的影响[J].中国老年医学杂志,2012,32(24):5482-5483.
  • 6Morreale VM, Herman BH, Der-M inassian V, et al. A brain-tumor model utilizing stereotactic implantation of a permanent cannula[J].J Neurosurg,1993,78(6): 959-965.
  • 7Penuelas S, AnidoJ, Prieto-Sanchez RM, et al. TGF -beta increases glioma-initiating cell self-renewal through the induction of LIF in hu?man glioblastoma[J]. Cancer Cell,2009,15(6) :315-327.
  • 8Teicher BA. Transforming growth factor-beta and the immune response to malignant disease[J]. Clin Cancer Res, 2007 , 13 ( 21 ) : 6247-6251.
  • 9Johnson BF, Clay TM, Hobeika AC, et al. Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and po?tential for new therapy[J]. Expert Opin Bioi Ther, 2007 , 7 ( 4 ) : 449- 460.
  • 10Kalinski P. Regulation of immune responses by prostaglandin E2[J] . J Immunol,2012,188(1) :21-28.

二级参考文献20

  • 1王煜,雷霆,牛洪泉,董震,董芳永,柳再明,薛德麟.树突状细胞瘤内注射和化疗联合治疗脑胶质瘤的实验研究[J].中华神经外科杂志,2006,22(3):184-186. 被引量:11
  • 2董伦,浦佩玉,王虎,王广秀,康春生,焦德让.星形细胞肿瘤表皮生长因子受体与p53基因的异常表达[J].中华病理学杂志,2006,35(4):232-236. 被引量:10
  • 3Wang D, DuBois RN. Prostaglandins and cancer. Gut, 2006,55 (1) :115-122.
  • 4Onguru O, Gamsizkan M, Ulutin C, et al. Cyclooxygenase-2 (Cox-2) expression and angiogenesis in glioblastoma. Neuropathology, 2008, 28( 1 ) :29-34.
  • 5Buccoliero AM, Caldarella A, Gheri CF, et al. Inducible cyclooxygenase (COX-2) in glioblastoma-clinical and immunohistochemical ( COX-2-VEGF ) correlations. Clin Neuropathol, 2006, 25 (2) :59-66.
  • 6Sminia P, Stoter TR, van der Valk P, et al. Expression of cyclooxygenase-2 and epidermal growth factor receptor in primary and recurrent glioblastoma multiforme. J Cancer Res Clin Oncol, 2005, 131 (10) :653-661.
  • 7Maiti AK, Ghosh K, Chatterjee U, et al. Epidermal growth factor receptor and proliferating cell nuclear antigen in astrocytomas. Neurol India, 2008, 56(4) :456-462.
  • 8Xu K, Shu HK. EGFR Activation Results in Enhanced Cyclooxygenase-2 Expression through p38 Mitogen-Activated Protein Kinase-Dependent Activation of the Spl Sp3 Transcription Factors in Human Gliumas. Cancer Res, 2007, 67 (13) : 6121-6129.
  • 9Ali S, EI-Rayes BF, Sarkar FH, et al. Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy. Mol Cancer Ther, 2005,4 (12) : 1943-1951.
  • 10Okada H, Kohanbash G,Zhu X, et al. Immunotherapeutic approaches for glioma. Crit Rev Immunol,2009,29 : 1-42.

共引文献7

同被引文献61

  • 1颜世清,张浩,孔令胜,郭强,张军臣,靳峰.儿童症状性透明隔囊肿的临床诊断特征及其神经内镜治疗[J].中华诊断学电子杂志,2013,1(1). 被引量:2
  • 2刘晓智,康春生,张志勇,贾志凡,王广秀,浦佩玉.U251胶质瘤荷瘤鼠皮下模型的建立及其表皮生长因子受体通路成员异常表达[J].中国现代神经疾病杂志,2007,7(1):71-75. 被引量:3
  • 3Gerstner ER, Sorensen AG, Jain RK, et al. Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomas [ J ]. Curr Opin Neurol, 2008,21 ( 6 ) : 728- 735.
  • 4Bar JK, Zub L, Lis-Nawara A, et al. Expression and Interactions Be- tween Cell Adhesion Molecules CD44v6 and E-Cadherin in Human Gliomas[ J].Adv Clin Exp Med,2014,23(5) :827-834.
  • 5Vilgrain I, Sidib A, Polena H, et al. Evidence for post-translational processing of vascular endothelial ( VE ) -cadherin in brain tumors : to- wards a candidate biomarker [ J ]. PLoS One, 2013,8 ( 12 ) : e80056- 80060.
  • 6Nissou MF, El Atifi M, Guttin A, et al. Hypoxia-induced expression of VE-eadherin and filamin B in glioma cell cultures and pseudopalisade structures[J]. J Neurooncol,2013,113(2) :239-249.
  • 7Wallez Y,Cand F, Cruzalegui F, et al. Src kinase phosphorylates vas- cular endothelial-eadherin in response to vascular endothelial growth factor:identification of tyrosine 685 as the unique target site [ J ]. On- cogene , 2007,26 (7) : 1067-1077.
  • 8Sidib6 A,Mannic T, Arboleas M, et al. Soluble VE-cadherin in rheu- matoid arthritis patients correlates with disease activity: evidence for tumor necrosis factor c-induced VEcadherin cleavage [ J ]. Arthritis Rheum ,2012,64( 1 ) :77-87.
  • 9Lambeng N, Wallez Y, Rampon C, et al. Vascular endothelial-cadherin tyrosine phosphorylation in angiogenic and quiescent adult tissues[ J]. Circ Res,2005,96(3) :384-391.
  • 10Weller M, Gorlia T, Cairncross JG, et al. Prolonged survival with valp- roic acid use in the EORTC/NCIC temozolomide trial for glioblastoma [J]. N Engl J Med,2011,352(12) :987-996.

引证文献6

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部